Browse News
Filter News
Found 470 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Mill Creek's Frontier Dermatology Is First in Washington to Offer Nonsurgical Treatment for Common Skin Cancer Using Image-Guided Superficial Radiation Therapy
4/17/2024
SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy, a nonsurgical treatment with the highest cure rate for common skin cancers, announced its availability in Washington at an event at Frontier Dermatology in Mill Creek.
-
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
4/11/2024
Heron Therapeutics, Inc., a commercial-stage biotechnology company, announced that it will host an Investor Day on Wednesday, May 15, 2024 in New York City, beginning at 9:30 am ET.
-
ADARx Pharmaceuticals Appoints Dr. Chris Storgard as Chief Medical Officer
4/2/2024
ADARx Pharmaceuticals, Inc. today announced the appointment of Chris Storgard, M.D., as Chief Medical Officer (CMO).
-
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
3/28/2024
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig Collard, Chief Executive Officer of Heron, will participate in a fireside chat on Wednesday, April 10, 2024, at 11:00 AM ET at the 23rd Annual Needham Virtual Healthcare Conference.
-
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
3/12/2024
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2023 and highlighted recent corporate updates.
-
Calyx and Invicro agree to combine to create a global leader in medical imaging and software solutions for the clinical research community
3/7/2024
Calyx, a leading technology-enabled provider of Medical Imaging services and IRT/RTSM to drug developers, and Invicro, a next-generation quantitative imaging biomarker company and pre-eminent development partner to pharma sponsors, have agreed to combine their business.
-
Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
2/28/2024
Heron Therapeutics, Inc. today announced that the company will host a conference call and live webcast on Tuesday, March 12, 2024, at 4:30 p.m. ET to report fourth quarter and full year 2023 financial results and discuss recent business highlights.
-
Acadia Announces Additions to Executive Team - Jan 31, 2024
1/31/2024
Acadia Pharmaceuticals Inc. announced two new appointments to its executive team.
-
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
1/23/2024
Heron Therapeutics, Inc. (Nasdaq: HRTX) today announced that the U.S. Food and Drug Administration (the "FDA") has approved its supplemental New Drug Application ("NDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided.
-
After a quiet start to 2024, the FDA is expected to decide on three applications over the next two weeks, including one for a nasal powder migraine treatment.
-
CrossLink Life Sciences and Heron Therapeutics Partner to Boost ZYNRELEF® Promotion for Post-Operative Pain
1/11/2024
Life Sciences, a leading medical device distributor and sales organization, is proud to announce a groundbreaking five-year partnership with Heron Therapeutics, Inc
-
Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain
1/7/2024
Heron Therapeutics, Inc. announced that it has entered into a five-year distributor partnership with CrossLink Life Sciences, LLC to expand the sales network supporting ZYNRELEF® extended-release solution.
-
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
11/14/2023
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company") today announced financial results for the three and nine months ended September 30, 2023 and highlighted recent corporate updates.
-
Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023
11/7/2023
Heron Therapeutics, Inc. (Nasdaq: HRTX) today announced that the company will host a conference call and live webcast on Tuesday, November 14, 2023 at 4:30 p.m. ET to report third quarter 2023 financial results and discuss recent business highlights.
-
Chiesi Global Rare Diseases Announces Multiple Presentations at SSIEM Annual Symposium 2023
9/1/2023
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, announced multiple presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 being held August 29 - September 1, 2023, in Jerusalem, Israel.
-
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
8/14/2023
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company") today announced financial results for the three and six months ended June 30, 2023 and highlighted recent corporate updates.
-
Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
8/7/2023
Heron Therapeutics, Inc. (Nasdaq: HRTX), today announced that the company will host a conference call and live webcast on Monday, August 14, 2023 at 4:30 p.m. ET to report second quarter 2023 financial results and discuss recent business highlights.
-
Heron Therapeutics Announces Cost Reduction Plan and Restructuring
7/24/2023
Heron Therapeutics, Inc. today announced a cost reduction plan and a corporate restructuring, following a strategic review of the business conducted by the new management team.
-
Eurofins Genomics Blue Heron launches IVT mRNA Synthesis Service: The Future of Gene Expression
6/29/2023
Eurofins Genomics Blue Heron is thrilled to announce the launch of our cutting-edge IVT mRNA Synthesis Service.